191873-41-3 Usage
Description
1-Deoxy-1-[[2-[(ethoxycarbonyl)amino]-5-[[(4-fluorophenyl)methyl]amino]phenyl]amino] β-D-Glucopyranuronic Acid, also known as Retigabine N-β-D-Glucuronide, is a major metabolite of the antiepileptic drug Retigabine (R189050). It is produced via N-glucuronidation in humans and has potential applications in the pharmaceutical industry due to its association with the antiepileptic drug.
Uses
Used in Pharmaceutical Industry:
1-Deoxy-1-[[2-[(ethoxycarbonyl)amino]-5-[[(4-fluorophenyl)methyl]amino]phenyl]amino] β-D-Glucopyranuronic Acid is used as a metabolite for the antiepileptic drug Retigabine (R189050) for the treatment of epilepsy and seizure disorders. It is produced via N-glucuronidation in humans, which may contribute to the drug's efficacy and safety profile.
Used in Research and Development:
In the field of pharmaceutical research and development, 1-Deoxy-1-[[2-[(ethoxycarbonyl)amino]-5-[[(4-fluorophenyl)methyl]amino]phenyl]amino] β-D-Glucopyranuronic Acid can be used as a starting point for the development of new antiepileptic drugs or for studying the metabolism and pharmacokinetics of Retigabine.
Used in Quality Control and Standardization:
The sodium salt of Retigabine N-β-D-Glucuronide can be used in the quality control and standardization of Retigabine formulations, ensuring the consistency and potency of the drug in various pharmaceutical products.
Check Digit Verification of cas no
The CAS Registry Mumber 191873-41-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,1,8,7 and 3 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 191873-41:
(8*1)+(7*9)+(6*1)+(5*8)+(4*7)+(3*3)+(2*4)+(1*1)=163
163 % 10 = 3
So 191873-41-3 is a valid CAS Registry Number.
191873-41-3Relevant articles and documents
In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices
McNeilly,Torchin,Anderson,Kapetanovic,Kupferberg,Strong
, p. 431 - 441 (1997)
1. The metabolic profile of D-23129, a new anticonvulsant agent, was studied in vitro using human liver microsomes and fresh liver slices. 2. Oxidative metabolism appeared to be minimal with D-23129. The percent mean total radioactivity not associated with the parent compound recovered from oxidative metabolism studies from three individual liver donors was 0.7% ± 0.6 SD and was not significantly different from [14C]-D-23129 incubated with heat inactivated microsomes, mean = 0.5% ± 0.4 SD. 3. Phase II conjugation dominated the metabolism of D-23129 producing two distinct N-glucuronides as the primary metabolites. These metabolites were identified by electrospray ionization LC/MS. 4. The apparent K(m), for one of the glucuronide metabolites was determined in human liver microsome preparations from two individual liver donors to be 131 and 264 μM respectively. V(max) determined for the same microsomal preparations yielded 48.9 and 59.9 pmol/min/mg protein.
